Acenaphthene

Acenaphthene

SCHEMBL1279642

O=C1C=CC(=O)C=C1.c1cc2c3c(cccc3c1)CC2

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 8/20 0.45
HPGD P15428 5/20 0.45
KDM4E B2RXH2 4/20 0.45
CYP3A4 P08684 4/20 0.44
TSHR P16473 2/20 0.44
CYP1A2 P05177 2/20 0.42
TYMS P04818 2/20 0.42
CYP2C19 P33261 1/20 0.42
PARP1 P09874 2/20 0.41
CES1 P23141 2/20 0.39
BCHE P06276 2/20 0.39
CES2 O00748 1/20 0.39
MCL1 Q07820 1/20 0.39
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acenaphthene SCHEMBL598252 0.85 TSHR (0.57) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL29386207 0.85 TSHR (0.57) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL28028969 0.85 TSHR (0.57) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL9017 0.85 TSHR (0.57) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL1162573 0.85 TSHR (0.57) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL3416108 0.85 TSHR (0.57) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL27807110 0.83 HSD17B10 (0.50) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL27924424 0.83 HSD17B10 (0.50) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL30729939 0.83 TSHR (0.55) HSD17B10LMNAALDH1A1HPGDKDM4E
Acenaphthene SCHEMBL29586283 0.83 TSHR (0.55) HSD17B10LMNAALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1835138-B Solid electrolytic capacitor and process for the production thereof MUTATA MFG CO LTD 2012-09-05 CN claimed
CN-101379100-A Production of isotactic and regiorandom polypropylene based polymer and block copolmyers CORNELL RES FOUNDATION INC (US) 2009-03-04 CN claimed
CN-1835138-A Solid electrolytic capacitor and process for the production thereof SHOWA DENKO KK (JP) 2006-09-20 CN claimed
CN-1350552-A Multistage process for the (co) polymerization of olefins BASEL TECHNOLOGY COMPANY B V (NL) 2002-05-22 CN claimed
CN-1297569-A Solid electrolytic capacitor and method for manufacturing the same SHOWA DENKO KK (JP) 2001-05-30 CN claimed
CN-1292818-A Novel dicarbonyl reductase and gene encoding same TAISHO PHARMACEUTICAL CO LTD (JP) 2001-04-25 CN claimed
JP-61158908-A None JP disclosed
US-20260150491-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT CANON KABUSHIKI KAISHA (JP) 2026-05-28 US disclosed
EP-4750286-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT Canon Kabushiki Kaisha (JP) 2026-05-27 EP disclosed
CN-121108200-B Nickel complex, preparation method, catalyst composition and application thereof, and method for copolymerization and homopolymerization of ethylene and alpha-olefin 中石油(上海)新材料研究院有限公司 2026-05-19 CN disclosed
EP-3596184-B1 ADHESIVE BONDING COMPOSITION AND ELECTRONIC COMPONENTS PREPARED FROM THE SAME IMMUNOLIGHT LLC (US) 2025-11-19 EP disclosed
CN-119873755-A Application of quinone compound as photocatalyst in photocatalytic hydrogen peroxide production 北京工业大学 2025-04-25 CN disclosed
US-12076579-B2 Energy augmentation structures in adhesive bonding compositions IMMUNOLIGHT, LLC (US) 2024-09-03 US disclosed
US-4243791-A Anaerobic adhesives ROCOL LIMITED (GB) 1981-01-06 US disclosed
US-4235686-A POLYURETHANE, UNSATURATED POLYESTER, AND ETHYLENICALLY UNSATURATED MONOMER IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1980-11-25 US disclosed
US-4216078-A Hydrogenation of petroleum liquids using quinone catalysts EXXON RESEARCH & ENGINEERING CO. (US) 1980-08-05 US disclosed
US-4205988-A Photochromic method involving an aromatic amine ASAHI KASEI K. K. (JP) 1980-06-03 US disclosed
US-4119510-A Photocurable diisocyanate compositions PHILLIPS PETROLEUM COMPANY (US) 1978-10-10 US disclosed
US-4051012-A DISTILLATION, HYDROGENATION, CIRCULATION EXXON RESEARCH & ENGINEERING CO. (US) 1977-09-27 US disclosed
US-4049537-A SLURRYING COAL, SOLVENT, AND A QUINONE, CONTACTING WITH HYDROGEN EXXON RESEARCH & ENGINEERING CO. (US) 1977-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260150491-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT NR2E3, RORB, RORA HSD17B10 2628/4885LMNA 1745/4885ALDH1A1 256/4885
US-12076579-B2 Energy augmentation structures in adhesive bonding compositions FN1, ADIPOR1, ICAM1 HSD17B10 4041/4885LMNA 2709/4885ALDH1A1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.